ImClone Hammered as Sales Lag Estimates

ImClone Hammered as Sales Lag Estimates
Scandal-plagued ImClone Systems may have fallen off the road to recovery.
While the company’s second-quarter earnings beat Wall Street estimates, the stock plunged yesterday on disappointing sales of the company’s key cancer drug.


Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Subscribe!